Stock data
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS) reported net income of -US$15.28M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$42.97M | -US$15.28M | — |
| 2024 | — | — | -US$27.55M | -US$62.29M | — |
| 2023 | — | — | -US$23.41M | -US$27.03M | — |
| 2022 | — | — | -US$32.56M | -US$41.31M | — |
| 2021 | — | — | -US$38.63M | -US$43.24M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$17.96M | — |
| 2026-03-31 | — | -US$13.69M | — |
| 2025-12-31 | — | -US$12.32M | — |
| 2025-09-30 | — | -US$10.16M | — |
| 2025-06-30 | — | -US$8.00M | — |
| 2025-03-31 | — | US$15.19M | — |
| 2024-12-31 | — | -US$12.11M | — |
| 2024-09-30 | — | -US$40.22M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.